Suppr超能文献

透析液钙处方对新接受血液透析患者死亡率的影响。

The effects of dialysate calcium prescription on mortality outcomes in incident patients on hemodialysis.

作者信息

Ter Meulen Karlien J, Carioni Paola, Bellocchio Francesco, van der Sande Frank M, Bouman Heleen J, Stuard Stefano, Neri Luca, Kooman Jeroen P

机构信息

Department of Internal Medicine, Division of Nephrology, Maastricht University Medical Centre+, Maastricht, the Netherlands.

Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands.

出版信息

Clin Kidney J. 2024 Oct 4;17(10):sfae288. doi: 10.1093/ckj/sfae288. eCollection 2024 Oct.

Abstract

BACKGROUND

The appropriate prescription of dialysate calcium concentration for hemodialysis is debated. We investigated the association between dialysate calcium and all-cause, cardiovascular mortality and sudden cardiac death.

METHODS

In this historical cohort study, we included adult incident hemodialysis patients who initiated dialysis between 1 January 2010 and 30 June 2017 who survived for at least 6 months (grace period). We evaluated the association between dialysate calcium 1.25 or 1.50 mmol/l and outcomes in the 2 years after the grace period, using multivariable Cox regression models. Moreover, we examined the association between the serum dialysate to calcium gradient and outcomes.

RESULTS

We included 12 897 patients with dialysate calcium 1.25 mmol/l and 26 989 patients with dialysate calcium 1.50 mmol/l. The median age was 65 years, and 61% were male. The unadjusted risk of all-cause mortality was higher for dialysate calcium 1.50 mmol/l [hazard ratio (HR) 1.07, 95% confidence intervals (CI) 1.01-1.12]. However, in the fully adjusted model, no significant differences were noted (HR 1.05, 95% CI 0.99-1.12). Similar results were observed for the risk of cardiovascular mortality (HR 1.03, 95% CI 0.94-1.13). Adjusted risk of sudden cardiac death was lower for dialysate calcium 1.50 mmol/l (HR 0.81, 95% CI 0.67-0.97). Significant and positive associations with all outcomes were observed with larger serum-to-dialysate calcium gradients, primarily mediated by the serum calcium level.

CONCLUSIONS

In contrast to the unadjusted analysis that showed a higher risk for dialysate calcium of 1.50 mmol/l, after adjusting for confounders, there were no significant differences in the risk of all-cause and cardiovascular mortality between dialysate calcium concentrations of 1.50 and 1.25 mmol/l. After adjustment, a lower risk of sudden cardiac death was observed in patients with dialysate calcium 1.50 mmol/l. A higher serum-to-dialysate calcium gradient is associated with an increased risk for adverse outcomes.

摘要

背景

血液透析中透析液钙浓度的合适处方存在争议。我们研究了透析液钙与全因死亡率、心血管死亡率及心源性猝死之间的关联。

方法

在这项历史性队列研究中,我们纳入了2010年1月1日至2017年6月30日开始透析且存活至少6个月(宽限期)的成年新发血液透析患者。我们使用多变量Cox回归模型评估宽限期后2年内透析液钙浓度为1.25或1.50 mmol/L与结局之间的关联。此外,我们还研究了血清透析液钙梯度与结局之间的关联。

结果

我们纳入了12897例透析液钙浓度为1.25 mmol/L的患者和26989例透析液钙浓度为1.50 mmol/L的患者。中位年龄为65岁,男性占61%。透析液钙浓度为1.50 mmol/L时,未经调整的全因死亡风险更高[风险比(HR)1.07,95%置信区间(CI)1.01 - 1.12]。然而,在完全调整模型中,未观察到显著差异(HR 1.05,95% CI 0.99 - 1.12)。心血管死亡率风险也有类似结果(HR 1.03,95% CI 0.94 - 1.13)。透析液钙浓度为1.50 mmol/L时,调整后的心源性猝死风险较低(HR 0.81,95% CI 0.67 - 0.97)。血清与透析液钙梯度越大,与所有结局均呈显著正相关,主要由血清钙水平介导。

结论

与未经调整的分析显示透析液钙浓度为1.50 mmol/L风险较高相反,在调整混杂因素后,透析液钙浓度为1.50 mmol/L和1.25 mmol/L之间的全因死亡率和心血管死亡率风险无显著差异。调整后,透析液钙浓度为1.50 mmol/L的患者心源性猝死风险较低。血清与透析液钙梯度较高与不良结局风险增加相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b770/11462444/01ff9a59f8cf/sfae288fig1g.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验